Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Innovent/Lilly Announce China Approval for Sixth Indication of PD-1 Drug

publication date: Jun 27, 2022

Suzhou Innovent Biologics and Lilly announced their partnered PL-1 inhibitor was approved in China for its sixth indication: first-line treatment of difficult gastric or gastroesophageal junction adenocarcinoma. The regimen combines Innovent’s Tyvyt® (sintilimab injection) with fluorouracil and platinum-based chemotherapy. Sintilimab is a PD-1 immunoglobulin G4 monoclonal that binds to PD-1 molecules on the surface of T-cells, reactivating T-cells to kill cancer cells. Innovent is conducting more than 20 clinical studies of sintilimab in a variety of cancers, including over 10 registrational/pivotal clinical trials. More details....

Stock Symbols: (HK: 01801) (NYSE: LLY)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital